- Home
- SPE vs MNOV Comparison
SPE vs MNOV Comparison
Compare SPE & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPE | MNOV |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 137.8M |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SPE | MNOV |
|---|---|---|
| Price | $12.60 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 41.0K | ★ 902.1K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $12.42 | $1.17 |
| 52 Week High | $15.67 | $3.90 |
Technical Indicators
Market Signals| Indicator | SPE | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 22.99 | 43.26 |
| Support Level | N/A | $1.28 |
| Resistance Level | $13.71 | $3.90 |
| Average True Range (ATR) | 0.18 | 0.38 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 19.83 | 6.56 |
Price Performance
Historical ComparisonAbout SPE Special Opportunities Fund Inc
Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.